Citadel Advisors
EUCRU

Citadel Advisors’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Citadel Advisors’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,053
Closed -$100K – 15023
2021
Q4 		$100K Hold
10,053
– – ﹤0.01% 12730
2021
Q3 		$101K Sell
10,053
-1,115
-10% -$11.1K ﹤0.01% 12857
2021
Q2 		$114K Buy
+11,168
New +$112K ﹤0.01% 12798

Other funds holding EUCRU

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Citadel Advisors's EUCRU Position: Q1 2022 in Review

Citadel Advisors sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q1 2022, closing a stake of 10,053 shares — an estimated $100K sold.

Citadel Advisors first reported a position in EUCRU in Q2 2021 and held it in 3 quarters. The position peaked at $114K in Q2 2021. 19 funds tracked by Wall St. Rank hold EUCRU as of Q1 2022.

  • Citadel Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
  • Citadel Advisors sold 10,053 Eucrates Biomedical Acquisition Corp. Unit shares in Q1 2022, an estimated $100K.
  • Citadel Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q2 2021 and held it in 3 quarters.
  • Citadel Advisors's Eucrates Biomedical Acquisition Corp. Unit position peaked at $114K in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.